docetaxel anhydrous has been researched along with arctiin in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (arctiin) | Trials (arctiin) | Recent Studies (post-2010) (arctiin) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 313 | 10 | 225 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Feng, T; Gu, X; Guo, Y; Li, J; Li, S; Liu, X; Liu, Y; Shen, W; Tsai, HI; Wu, F; Zhang, J; Zhang, L | 1 |
1 other study(ies) available for docetaxel anhydrous and arctiin
| Article | Year |
|---|---|
Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arctium; Asia, Eastern; Cell Line, Tumor; Cell Proliferation; DNA; Docetaxel; Drug Evaluation, Preclinical; Drug Synergism; Female; Fluorescent Antibody Technique; Furans; Humans; Hydrogen Bonding; Lignans; Mice, Nude; Molecular Docking Simulation; Plants, Medicinal; Protein Domains; Signal Transduction; STAT3 Transcription Factor; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |